ABBOTT LABORATORIES — Regulatory Filings 2011

Feb 22, 2011

8-K 1 a11-6136_18k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

*FORM 8-K*

*CURRENT REPORT*

*Pursuant to Section 13 or 15(d) of the*

*Securities Exchange Act of 1934*

*February 18, 2011*

Date of Report (Date of earliest event reported)

*ABBOTT LABORATORIES*

(Exact name of registrant as specified in its charter)

Illinois	1-2189	36-0698440
(State or other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

*100 Abbott Park Road*

*Abbott Park, Illinois 60064-6400*

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (847) 937-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\rcheney\11-6136-1\task4501850\6136-1-ba.htm',USER='rcheney',CD='Feb 22 12:55 2011'

Item 5.03	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On February 18, 2011, Abbott’s Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of ten persons, effective April 29, 2011. Abbott’s by-laws currently provide that the Board of Directors shall consist of thirteen persons.
Item 9.01	Financial Statements and Exhibits
	Exhibit No.	Exhibit
	3.1	By-Laws of Abbott Laboratories, as amended and restated effective April 29, 2011.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\rcheney\11-6136-1\task4501850\6136-1-ba.htm',USER='rcheney',CD='Feb 22 12:55 2011'

*SIGNATURE*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Thomas C. Freyman
Thomas C. Freyman
Executive Vice President, Finance
and Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\rcheney\11-6136-1\task4501850\6136-1-ba.htm',USER='rcheney',CD='Feb 22 12:55 2011'

*EXHIBIT INDEX*

Exhibit No.	Exhibit
3.1	By-Laws of Abbott Laboratories, as amended and restated effective April 29, 2011.

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\rcheney\11-6136-1\task4501850\6136-1-ba.htm',USER='rcheney',CD='Feb 22 12:55 2011'